

Liza M. Walsh (LW4095)
 CONNELL FOLEY LLP
 85 Livingston Avenue
 Roseland, New Jersey 07068-1765
 (973) 535-0500

Gerald Sobel
 Joel Katcoff
 David K. Barr
 KAYE SCHOLER LLP
 425 Park Avenue
 New York, New York 10022
 (212) 836-8000

Paul H. Berghoff
 Curt J. Whitenack
 McDONNELL BOEHNEN HULBERT
 & BERGHOFF LLP
 300 South Wacker Drive
 Chicago, Illinois 60606
 (312) 913-0001

Attorneys for Plaintiffs

**UNITED STATES DISTRICT COURT
 DISTRICT OF NEW JERSEY**

<div>AVENTIS PHARMACEUTICALS INC., et al.,</div> <div>Plaintiffs,</div> <div>v.</div>	
<div>BARR LABORATORIES, INC.,</div> <div>Defendant.</div>	<div>Civil Action No. 01-3627 (JAG consolidated)</div>
<div>TEVA PHARMACEUTICALS, USA, INC.,</div> <div>Defendant.</div>	<div>Civil Action No. 03-487 (JAG)</div>
<div>BARR LABORATORIES, INC. and RANBAXY LABORATORIES LIMITED and RANBAXY PHARMACEUTICALS, INC.,</div> <div>Defendants.</div>	<div>Civil Action No. 04-1064 (JAG)</div>
<div>TEVA PHARMACEUTICALS USA, INC. and AMINO CHEMICALS LTD.,</div> <div>Defendants.</div>	<div>Civil Action No. 04-1078 (JAG)</div>

ORDER TO SHOW CAUSE

THIS MATTER having been opened to the Court by Connell Foley LLP, Kaye Scholer LLP, McDonnell, Boehnen, Hulbert, Berghoff LLP attorneys for the plaintiffs, Aventis Pharmaceuticals Inc., Merrell Pharmaceuticals Inc. and Carderm Capital L.P. (collectively “Aventis”) and DeCotiis, FitzPatrick, Cole & Wisler LLP and Nixon Peabody LLP, attorneys for AMR Technology, Inc. and Albany Molecular Research, Inc. (collectively “AMR”), by way of Order to Show Cause why Plaintiffs’ Motion for a Preliminary Injunction or, Alternatively, for an Expedited Trial should not be granted against Barr Laboratories, Inc., Teva Pharmaceuticals USA, Ranbaxy Laboratories Ltd., Ranbaxy Pharmaceuticals, Inc. (“Ranbaxy”) and Amino Chemicals Ltd. (“Amino”); and the Court having considered Declarations of Joel Katcoff, Jeremy Noe, Frank M. Musat, Eli O. Meltzer, M.D., Mark T. Frost, Jerry L. Atwood, M.D., Michael L. Gross, M.D., James A. Karboski, D. Pharm. Richard P. Rozeck, Ph.D. and the Memorandum in Support of Plaintiffs’ application; and it

APPEARING that Aventis is the owner of US Patent Nos. 6,037,353 (the “‘353 patent”), 6,187,791 (the “‘791 patent”) and 6,399,632 (the “‘632 patent”) (collectively the “Method Patents”) for administration of fexofenadine to certain patient subpopulations, and has sued Barr Laboratories, Inc. (“Barr”), Teva Pharmaceuticals USA (“Teva”) and others for infringement of the ‘353, ‘791 and ‘632 patents; and it

FURTHER APPEARING that AMR is the owner and that Aventis is the exclusive licensee of US Patent No. 5,750,703 (the “‘703 patent” or “Process Patent”) for the making, using or selling of fexofenadine or fexofenadine products manufactured by the patented process, and has sued Barr, Teva, Ranbaxy Laboratories Ltd., Ranbaxy

Pharmaceuticals, Inc. ("Ranbaxy") Amino Chemicals Ltd. ("Amino") and others for the infringement of the '703 patent; and it

FURTHER APPEARING that Barr and Teva have launched their 30 mg, 60 mg and 180 mg generic fexofenadine tablet versions of Allegra[®], and it

FURTHER APPEARING that notice of Aventis and AMR's application has been given to Barr, Teva, Ranbaxy and Amino's attorneys and Aventis and AMR's attorneys have served upon Barr, Teva, Ranbaxy and Amino's attorneys with copies of this proposed Order, the Declarations of Joel Katcoff, Jeremy Noe, Frank M. Musat, Eli O. Meltzer, M.D., Mark T. Frost, Jerry L. Atwood, M.D., Michael L. Gross, M.D. Declaration of James A. Karboski and Richard P. Rozeck, Ph.D.; and

The Court having considered the positions of the parties, and for good cause shown;

IT IS ON THIS ____ day of September, 2005 **ORDERED** that on the ____ day of _____, at ____ a.m. / p.m., Barr, Teva, Ranbaxy and Amino shall show cause before the Honorable Joseph A. Greenaway, sitting at the Martin Luther King Jr. Federal Building and United States Courthouse, 50 Walnut Street, Newark, New Jersey, why an Order should not be entered preliminarily enjoining defendants Teva Pharmaceuticals USA, Inc. ("Teva") and Barr Laboratories, Inc. ("Barr") from marketing fexofenadine tablets pursuant to labeling which specifically recites the administration of fexofenadine to subpopulations of (i) hepatically impaired patients; (ii) patients also taking ketoconazole and erythromycin; and (iii) patients susceptible to certain cardiac effects; and preliminarily enjoining defendants Barr, Teva, Ranbaxy and Amino from making, using or selling fexofenadine or fexofenadine products manufactured by Ranbaxy and

Amino, pending a trial on and resolution of the liability issues in these cases and/or pending further Order of this Court; and it is further

ORDERED that defendants Barr, Teva, Ranbaxy and Amino shall file and serve any opposition papers to the within Order to Show Cause by ____ ____, 2005; and it is further

ORDERED that plaintiffs Aventis and AMR shall filed and serve any reply papers to defendants' opposition by _____, 2005; and it is further

ORDERED that a copy of this Order to Show Cause be served upon defendants Barr, Teva, Ranbax and Amino within 2 days of the date hereof; and it is further

ORDERED that the Court shall require Plaintiffs Aventis and AMR to post an appropriate bond on a date and in an amount to be determined by the Court in accordance with Rule 65(c) of the Federal Rules of Civil Procedure.

HONORABLE JOSEPH A.GREENAWAY, JR.
UNITED STATES DISTRICT JUDGE